Brief: Citius Oncology Signs Exclusive Commercialization Agreement With EVERSANA To Support Planned Q4 2025 Launch Of LYMPHIR
16/10/2025 13:49
Oct 16 (Reuters) - Citius Oncology Inc CTOR.O: CITIUS ONCOLOGY SIGNS EXCLUSIVE COMMERCIALIZATION AGREEMENT WITH EVERSANA TO SUPPORT PLANNED Q4 2025 LAUNCH OF LYMPHIR™ CITIUS ONCOLOGY INC: CO PLANS TO COMMERCIALLY LAUNCH LYMPHIR IN UNITED STATES IN Q4 2025 Source text: ID:nPn9H30nNa Further company coverage: CTOR.O
Recent news on Citius Oncology
See all newsCitius Oncology Inc reports results for the quarter ended June 30 - Earnings Summary
Citius Oncology Inc expected to post a loss of 5 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-AnaptysBio, Tesla, Intel
U.S. STOCKS ON THE MOVE-Dycom Industries, Robinhood, Brown-Forman
Citius rises as lymphoma drug shows benefit in patients before CAR-T therapy